Effect of reduction in brain amyloid levels on change in cognitive and functional decline in randomized clinical trials: An instrumental variable meta-analysis.

Menglan PangLing ZhuAudrey GabelleArie R GafsonRobert W PlattJames E GalvinPierre Krolak-SalmonIvana RubinoCarl de MoorShibeshih BelachewChangyu Shen

Published in: Alzheimer's & dementia : the journal of the Alzheimer's Association (2022)

A widely cited meta-analysis article concluded amyloid beta reduction does not substantially improve cognition. We identified data inconsistencies in the initial publication and found new trial data. We repeated the meta-analysis after correcting data inconsistencies and adding new trial data. Updated results suggested statistically significant clinical benefit of amyloid beta reduction. Amyloid beta is a viable biological target for the treatment and prevention of AD.

Keyphrases

systematic review
electronic health record
meta analyses
big data
clinical trial
study protocol
randomized controlled trial
phase iii
case control
white matter
data analysis
phase ii
machine learning
multiple sclerosis
deep learning
replacement therapy
artificial intelligence